Linda-Gail Bekker

Last updated

Linda-Gail Bekker
Fogarty-nih-50th-symposium-speaker-linda-gail-bekker (27774294837) (cropped).jpg
Bekker speaks at the John E. Fogarty International Center 50th anniversary symposium in 2018
Alma mater University of Cape Town
Rockefeller University
Employer(s) Desmond Tutu HIV Foundation
University of Cape Town
Organization International AIDS Society
Known forHIV/AIDS Research

Linda-Gail Bekker MBChB, DTMH, DCH, FCP(SA) is a Professor of Medicine and Chief Operating Officer of the Desmond Tutu HIV Foundation. She is also Director of the Desmund Tutu HIV Centre at the University of Cape Town. She is a Past President of the International AIDS Society (2016-18). [1]

Contents

Early life and education

Bekker was born in Zimbabwe. [2] She studied medicine at the University of Cape Town. [3] She intended on becoming a geriatrician, but completed a clinical rotation in KwaZulu-Natal and became interested in HIV and TB research. [4] She saw young people dying from HIV/AIDS and was frustrated that she couldn't help them. [5] Her PhD was funded by the John E. Fogarty International Center. [2] She worked in the Rockefeller University on host immunology. [2] Her doctoral advisor was Gilla Kaplan and she continues to work with her today. [6] [5]

Research and career

In 2009 she won the Royal Society Pfizer Award for her research into tuberculosis epidemiology. [7] [8] The funding supported her research in the Nyanga Primary Health Clinic in Cape Town. [8] Bekker is passionate about engagement with communities and peer led education programs. [9] Her community work looks to overcome stigma related to HIV and Tuberculosis. [10] The Desmond Tutu HIV Foundation, where Bekker serves as Chief Operating Officer, supports the wellbeing of people in South Africa's poorest communities. [11] Her husband, Robin Wood, serves as the Director and CEO. [12] She developed a mobile health van, known as the Tutu tester, which offers screening for pregnancy, high blood pressure, diabetes, HIV/AIDS, TB and obesity. [13] [10] She is Director of the Desmund Tutu HIV Centre at the University of Cape Town, where she integrates best practise and evidence-based information about adolescent treatment and prevention in a robust platform. [14] The centre is funded by the National Institutes of Health. [15] She developed Choices for Adolescent Methods of Prevention in South Africa (CHAMPS); which challenges young men's attitudes to circumcision, encourages young women to use contraception and investigates Pre-exposure prophylaxis. [16] She has also worked on Pregnancy and HIV/AIDS Seeking Equitable Study (PHASES) funded by the National Institutes of Health. [17] She studies the roll out of antiretroviral therapies. [18] [19] She is excited about HIV self-testing. [20]

In 2016 she was elected President of the International AIDS Society. [21] She gave the opening address at the International AIDS Society Conference in Paris, where she spoke about new prevention options such as Pre-exposure prophylaxis. [22] In 2018 she was elected to the board of the International AIDS Vaccine Initiative. [14] She is concerned about Donald Trump undermining the global HIV response. [23] [24] She has been a keynote speaker at World AIDS Day. [25]

She has contributed to The Conversation. [26] [27] [28] [29] Bekker enjoys painting and has used street theatre in her community work. [10]

Bekker serves as an advisor to the President's Emergency Plan for AIDS Relief. [30]

At the 2024 International AIDS Conference in Munich, Professor Bekker presented results from the PURPOSE-1 study of HIV prevention using twice-yearly injectable lenacapavir that demonstrated twice-yearly injection fully protects women from HIV infection. [31] [32] No participants receiving twice-yearly lenacapavir acquired HIV infection was also reported in The New England Journal of Medicine article. [33]

COVID-19

Bekker was the co-lead investigator, along with Glenda Gray, of the Sisonke trial that aimed to give the health-care workers in South Africa early access to COVID vaccines. [34] The phase 3b open label clinical trial ran from 17 February 2021 [35] to 15 May 2021, [36] with 478 733 doses given to health care workers. [37] The study tested the efficacy of the Jansen (J&J) vaccine when administered on large scale under South African conditions. [34]

Related Research Articles

<span class="mw-page-title-main">Tuberculosis</span> Infectious disease

Tuberculosis (TB), also known colloquially as the "white death", or historically as consumption, is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but it can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis. Around 10% of latent infections progress to active disease which, if left untreated, kill about half of those affected. Typical symptoms of active TB are chronic cough with blood-containing mucus, fever, night sweats, and weight loss. Infection of other organs can cause a wide range of symptoms.

<span class="mw-page-title-main">HIV vaccine development</span> In-progress vaccinations that may prevent or treat HIV infections

An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals. It is thought that an HIV vaccine could either induce an immune response against HIV or consist of preformed antibodies against HIV.

<span class="mw-page-title-main">HIV/AIDS in Africa</span>

HIV/AIDS originated in the early 20th century and has become a major public health concern and cause of death in many countries. AIDS rates vary significantly between countries, with the majority of cases concentrated in Southern Africa. Although the continent is home to about 15.2 percent of the world's population, more than two-thirds of the total population infected worldwide – approximately 35 million people – were Africans, of whom around 1 million have already died. Eastern and Southern Africa alone accounted for an estimate of 60 percent of all people living with HIV and 100 percent of all AIDS deaths in 2011. The countries of Eastern and Southern Africa are most affected, leading to raised death rates and lowered life expectancy among adults between the ages of 20 and 49 by about twenty years. Furthermore, life expectancy in many parts of Africa is declining, largely as a result of the HIV/AIDS epidemic, with life-expectancy in some countries reaching as low as thirty-nine years.

<span class="mw-page-title-main">Tropical medicine</span> Interdisciplinary branch of medicine

Tropical medicine is an interdisciplinary branch of medicine that deals with health issues that occur uniquely, are more widespread, or are more difficult to control in tropical and subtropical regions.

<span class="mw-page-title-main">Pre-exposure prophylaxis for HIV prevention</span> HIV prevention strategy using preventative medication for HIV-negative individuals

Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is a form of medication used to prevent HIV infection, the cause of HIV/AIDS.

<span class="mw-page-title-main">HIV/AIDS in South Africa</span> Health concern in South Africa

HIV/AIDS is one of the most serious health concerns in South Africa. South Africa has the highest number of people afflicted with HIV of any country, and the fourth-highest adult HIV prevalence rate, according to the 2019 United Nations statistics. About 8 million South Africans out of the 60 million population live with HIV.

Professor Sheila Dinotshe Tlou is a Botswana nurse, specialist in HIV/AIDS and women's health, and nursing educator. She was Minister of Health from 2004 to 2008. Professor Tlou is a distinguished advocate for human resources for health issues. She is a recognized visionary leader and champion.

The Royal Society Africa Prize has been awarded by the Royal Society since 2006 to African-based researchers at the start of their career who are making innovative contributions to the biological sciences in Africa. £60,000 is awarded as a grant for the recipient to carry out a research project that is linked to an African centre of scientific excellence, normally a University or equivalent research centre, and a further £5,000 is given directly to the prizewinner.

The United States Military HIV Research Program was initiated by the United States Congress in 1986, in reaction to the threat of lost effectiveness of U.S./Allied troops due to HIV infection. The mission of MHRP is to develop an HIV-1 vaccine, provide prevention, care, and treatment, and conduct meaningful HIV/AIDS research for the global community through the President's Emergency Plan for AIDS Relief (PEPFAR). It is centered at the Walter Reed Army Institute of Research (WRAIR), and has established five international research sites in Africa and Asia. MHRP also partners with the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Thailand. MHRP works closely with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), most notably in the development of the RV144 HIV vaccine in Thailand. MHRP is the largest research program supported by the HJF.

The Desmond Tutu HIV Foundation (DTHF) is a nonprofit organization founded to provide treatment for and conduct HIV/AIDS research. It is based in Cape Town, South Africa, and is managed with the Desmond Tutu HIV Centre at the University of Cape Town. The Foundation operates community sites throughout greater Cape Town, providing treatment, testing, and outreach services to at-risk communities.

Zeda Fran Rosenberg is an American microbiologist and epidemiologist, active in HIV biology and prevention. She is the chief executive officer of the International Partnership for Microbicides (IPM). IPM was founded by Rosenberg in 2002 and is a nonprofit organization dedicated to developing microbicides and other innovative HIV prevention products and making them available for women in developing countries.

HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus (HIV). HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community, or may be instituted by governments and community-based organizations as public health policies.

The XVIII International AIDS Conference was held in Vienna, Austria from July 18–23, 2010.

The Desmond Tutu TB Centre, also referred to as the DTTC or Desmond Tutu Tuberculosis Centre, is a research facility committed to raising awareness about tuberculosis and providing medical treatment and solutions to TB patients in South Africa. Founded in 2003 by Professor Nulda Beyers as the Centre for Tuberculosis Research and Education, the centre came under the patronage of Archbishop Desmond Tutu, Archbishop of South Africa and former TB survivor and, in 2005, changed its name to reflect the event. Since then, the DTTC has worked alongside Desmond Tutu to combat the health issue of TB in South Africa. It is currently directed by Professor Beyers.

<span class="mw-page-title-main">Quarraisha Abdool Karim</span>

Quarraisha Abdool Karim is an infectious diseases epidemiologist and co-founder and Associate Scientific Director of CAPRISA. She is a Professor in Clinical Epidemiology, Columbia University, New York and Pro-Vice Chancellor for African Health, University of KwaZulu-Natal, South Africa.

<span class="mw-page-title-main">Salim Abdool Karim</span> South African medical researcher

Salim S. Abdool Karim, MBChB, MMed, MS(Epi), FFPHM, FFPath (Virol), DipData, PhD, DSc(hc), FRS is a South African public health physician, epidemiologist and virologist who has played a leading role in the AIDS and COVID-19 pandemic. His scientific contributions have impacted the landscape of HIV prevention and treatment, saving thousands of lives.

Elizabeth Anne Bukusi FAAS is a research professor working within the field of obstetrics and gynaecology, and global health. Bukusi's main areas of research focus around sexually transmitted infections, women's health, reproductive health, and HIV care, prevention and treatment. Bukusi is the Chief Research Officer at the Kenya Medical Research Institute (KEMRI) and led a "landmark" study on the use of PrEP in Kenya.

Alash'le Grace Abimiku is a Nigerian executive director of the International Research Centre of Excellence at the Institute of Human Virology Nigeria and a professor of virology at the University of Maryland School of Medicine who takes interest in the prevention and treatment of HIV.

James Gita Hakim, was a Zimbabwean internist, clinical epidemiologist, cardiologist, researcher, university faculty and academic mentor. At the time of his death, he was Professor of Medicine and Former Chair of Internal Medicine at the University of Zimbabwe College of Health Sciences.

<span class="mw-page-title-main">Lenacapavir</span> Antiretroviral medication

Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. It is taken by mouth or by subcutaneous injection.

References

  1. ↑ Samarasekera, Udani (2021). "Linda-Gail Bekker—a leader at the service of the world". The Lancet Infectious Diseases. 21 (6). Elsevier BV: 778. doi:10.1016/s1473-3099(21)00283-8. ISSN   1473-3099. PMID   34051192. S2CID   235248719.
  2. 1 2 3 "Q and A with former Fogarty trainee Dr Linda-Gail Bekker". FIc. Retrieved 28 May 2018.
  3. ↑ "The NS Interview: Linda-Gail Bekker". www.newstatesman.com. 5 November 2009. Retrieved 28 May 2018.
  4. ↑ "Vax Report - Vax Report". www.vaxreport.org. Retrieved 28 May 2018.
  5. 1 2 "PHRI :: Gilla Kaplan, Ph.D." www.phri.org. Archived from the original on 27 June 2003. Retrieved 14 June 2021.
  6. ↑ "Gilla Kaplan". Bill & Melinda Gates Foundation. Archived from the original on 11 September 2013. Retrieved 14 June 2021.
  7. ↑ "South Africa: Linda-Gail Bekker Scoops Award for TB/HIV" . Health-e (Cape Town). 30 October 2009. Retrieved 14 June 2021.
  8. 1 2 "African scientist wins award for HIV and TB co-infection research - Science News". royalsociety.org. Retrieved 28 May 2018.
  9. ↑ "Professor Linda-Gail Bekker MBChB DTMH DCH FCP(SA) PhD | Infectious Disease & Molecular Medicine". www.idm.uct.ac.za. Archived from the original on 29 May 2018. Retrieved 28 May 2018.
  10. 1 2 3 "Linda-Gail Bekker: confronting the TB/HIV co-infection epidemic" (PDF). The Lancet. 13 February 2013. Retrieved 28 May 2018.
  11. ↑ "Linda-Gail Bekker". The Conversation. 21 July 2016. Retrieved 28 May 2018.
  12. ↑ "Desmond Tutu HIV Foundation | Background". Desmond Tutu HIV Foundation. Archived from the original on 6 October 2018. Retrieved 28 May 2018.
  13. ↑ "FABA (For Africa By Africans: Tutu Tester | Africa Strictly Business". www.africastrictlybusiness.com. Archived from the original on 29 May 2018. Retrieved 28 May 2018.
  14. 1 2 "Board of Directors". IAVI - International AIDS Vaccine Initiative. Archived from the original on 14 April 2017. Retrieved 14 June 2021.
  15. ↑ "Plenary Sessions - HIVR4P 2018". HIVR4P 2018. Archived from the original on 9 October 2014. Retrieved 14 June 2021.
  16. ↑ "CHAMPS". AVAC. 18 March 2014. Retrieved 28 May 2018.
  17. ↑ "Team". PHASES: Pregnancy & HIV/AIDS: Seeking Equitable Study. Retrieved 28 May 2018.
  18. ↑ "Conference Committees". www.aids2018.org. Retrieved 28 May 2018.
  19. ↑ Bekker, L.-G.; Wood, R. (1 November 2011). "TB and HIV co-infection: When to start antiretroviral therapy". Continuing Medical Education. 29 (10): 420. ISSN   2078-5143.
  20. ↑ "HIV Self-Test Granted CE Mark - Clinical Lab Products". Clinical Lab Products. Retrieved 28 May 2018.
  21. ↑ "Bekker, Linda-Gail - Virology Education". Virology Education. Retrieved 28 May 2018.
  22. ↑ "Professor Linda-Gail Bekker opens the International AIDS Symposium Conference | Desmond Tutu HIV Foundation". Desmond Tutu HIV Foundation. 1 August 2017. Archived from the original on 19 February 2018. Retrieved 14 June 2021.
  23. ↑ "Cutbacks in foreign aid for HIV treatment would produce great harm, generate few savings". Massachusetts General Hospital. Archived from the original on 29 May 2018. Retrieved 14 June 2021.
  24. ↑ "More than 200 Scientists, Researchers and Clinicians including the co-discoverer of HIV Denounce Trump Administration Policies that Undermine the Global HIV Response". Health GAP (Global Access Project). Archived from the original on 8 March 2018. Retrieved 14 June 2021.
  25. ↑ Expresso Show (4 December 2017), World Aids Day – Linda-Gail Bekker , retrieved 28 May 2018
  26. ↑ Bekker, Linda-Gail. "Three decades on, stigma still stymies HIV prevention and treatment". The Conversation. Retrieved 28 May 2018.
  27. ↑ Bekker, Linda-Gail. "Rings and things ... other ways to prevent HIV are on the cards". The Conversation. Retrieved 28 May 2018.
  28. ↑ Bekker, Linda-Gail. "Explainer: the how, what and why of the latest HIV vaccine trial". The Conversation. Retrieved 28 May 2018.
  29. ↑ Bekker, Linda-Gail. "AIDS conference 2016: the gains, the gaps, the next global steps". The Conversation. Retrieved 28 May 2018.
  30. ↑ "Southern Africa: Update On the President's Emergency Plan for Aids Relief (Pepfar)" . United States Department of State (Washington, DC). 26 July 2017. Retrieved 14 June 2021.
  31. ↑ Lay, Kat; correspondent, Global health (26 July 2024). "Doctor behind trial of HIV prevention drug recounts breakthrough moment". The Guardian. ISSN   0261-3077 . Retrieved 27 July 2024.{{cite news}}: |last2= has generic name (help)
  32. ↑ Sax, Paul (25 July 2024). "Lenacapavir PrEP Trial Brings Down the House at the International AIDS Conference". HIV and ID Observations. Retrieved 27 July 2024.
  33. ↑ Bekker, Linda-Gail; Das, Moupali; Abdool Karim, Quarraisha; Ahmed, Khatija; Batting, Joanne; Brumskine, William; Gill, Katherine; Harkoo, Ishana; Jaggernath, Manjeetha; Kigozi, Godfrey; Kiwanuka, Noah; Kotze, Philip; Lebina, Limakatso; Louw, Cheryl E.; Malahleha, Moelo (24 July 2024). "Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women". New England Journal of Medicine. doi:10.1056/NEJMoa2407001. ISSN   0028-4793. PMID   39046157.
  34. 1 2 Patel, Khadija; Malan, Mia (16 March 2021). "Trials, tinsel & tango: Go inside Linda-Gail Bekker's COVID world – Bhekisisa". Bhekisisa. Retrieved 26 July 2021.
  35. ↑ "J&J vaccines arrive in SA on Tuesday night". TimesLIVE. 16 February 2021. Retrieved 26 July 2021.
  36. ↑ Nair, Nivashni; Savides, Matthew (15 May 2021). "Final vaccine administered as part of Sisonke trial". TimesLIVE. Retrieved 26 July 2021.
  37. ↑ "Update On Covid-19 (16th May 2021)". SA Corona Virus Online Portal. 16 May 2021. Retrieved 26 July 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.